Copy link for New Approach for mRNA HIV Vaccine Passes First Human Trial
The first human trial of a new approach to an HIV vaccine has shown promising results, opening the door to a future jab for vaccination s most vexing enemy. The results also reveal a new framework for potentially staving off other viruses, like dengue, hepatitis C, and influenza, too.
The treatment a kind of pre-vaccine vaccine generated a very rare, special type of immune cell, known as naive B cells, which are capable of producing broadly neutralizing antibodies (bnAbs), according to Scripps.
After receiving the treatment, 97% of volunteers produced these naive B cells.